国际分级系统在散发性甲状腺髓样癌管理中的实用性
该回顾性队列研究纳入314例在比萨大学医院管理的散发性甲状腺髓样癌患者,评估国际甲状腺髓样癌分级系统(IMTCGS)预测疾病特异性生存(DSS)、无远处转移生存(DMFS)和无局部区域复发生存(LRFS)的性能。结果显示高通量组患者DSS、LRFS和DMFS均较低(p<0.01),但仅在局限性疾病亚组中高通量组LRFS显著低于低通量组,在已有颈部淋巴结转移(N1)、远处转移(M1)或RET突变(尤其M918T或插入缺失)时IMTCGS的预测作用变得不太相关。
要点
- IMTCGS可预测散发性MTC患者的DSS、LRFS和DMFS。
- 高通量肿瘤患者术前降钙素更高、肿瘤更大、多灶性和淋巴结转移更常见。
- 仅在局限性疾病患者中,高通量组LRFS显著低于低通量组。
核心结论
- 研究证实IMTCGS在预测散发性MTC的DSS、LRFS和DMFS方面有用。
- IMTCGS在复发和死亡风险较低的患者中效用最佳,可识别出临床行为更具侵袭性的罕见病例。
- 当诊断时已存在颈部淋巴结转移(N1)、远处转移(M1)或RET突变(尤其M918T或插入缺失)时,IMTCGS预测DSS、DMFS和LRFS的作用变得不太相关。
研究设计与样本
- 回顾性队列研究,评估314例在比萨大学医院管理的散发性MTC患者。
- 按诊断时疾病范围分为局限性疾病(183/314,58.3%)、区域性疾病(100/314,31.8%)和远处转移性疾病(31/314,9.9%)。
- 212/314(67.5%)患者有体细胞突变数据,由专家病理学家区分高通量和低通量肿瘤。
主要发现
- 根据IMTCGS,高通量肿瘤115/314(36.6%),低通量肿瘤199/314(63.4%)。
- 高通量组较低通量组术前降钙素更高(542 vs. 76 pg/mL,p < 0.01)、肿瘤更大(2.3 vs. 1.1 cm,p < 0.01)。
- 高通量组较低通量组多灶性更常见(22.6 vs. 12.1%,p = 0.01)、微小甲状腺外侵犯更常见(30.4 vs. 9.5%,p < 0.01)、淋巴结转移更常见(63.5 vs. 27.6%,p < 0.01)。
- 高通量组较低通量组DSS、LRFS和DMFS均更低(p < 0.01)。
- 按诊断时疾病范围分组后,仅在局限性疾病中,高通量组较低通量组LRFS显著更低;在其他亚组中,DSS、LRFS和DMFS均无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The international medullary thyroid carcinoma (MTC) grading system (IMTCGS) has been proposed as an independent tool to predict disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS). We aimed to evaluate the performance of IMTCGS in our series of sporadic MTCs and to compare its predictive power with conventional prognostic factors. Methods: In a retrospective cohort study, we evaluated data from 314 patients with sporadic MTC, all managed at the Pisa University Hospital. We divided patients according to the extent of the disease at diagnosis into localized (183/314, 58.3%) (confined to the thyroid), regional (100/314, 31.8%) (limited to the neck, involving surrounding thyroid tissues and/or regional lymph nodes), and distant (31/314, 9.9%) (distant metastases) disease. Data about somatic mutations were available in 212/314 (67.5%) patients. Expert pathologists differentiated high- and low-grade tumors. Results: According to the IMTCGS, 115/314 (36.6%) had high- and 199/314 (63.4%) patients had low-grade tumors. Patients with high-grade tumors showed higher preoperative calcitonin levels compared with low-grade (542 vs. 76 pg/mL, p < 0.01) as well as larger tumor size (2.3 vs. 1.1 cm, p < 0.01) and more frequent multifocality (22.6 vs. 12.1%, p = 0.01), minimal extrathyroidal extension (30.4 vs. 9.5%, p < 0.01), and lymph node metastases (63.5 vs. 27.6%, p < 0.01). Overall, patients with high-grade showed lower DSS, LRFS, and DMFS (p < 0.01). Grouping the whole cohort according to different disease extent at diagnosis, only in the case of localized disease, patients with high-grade tumors had significantly lower LRFS compared with low-grade. Similarly, in the other subgroups, we did not identify any difference in DSS, LRFS, and DMFS. Moreover, in the case of RET aggressive mutations, no differences in DSS, LRFS, and DMFS were observed between high- and low-grade tumors. Conclusions: We confirmed the usefulness of IMTCGS in predicting DSS, LRFS, and DMFS. However, it finds the best utility in patients with a lower risk of recurrence and mortality, identifying those rare cases with more aggressive clinical behavior. Conversely, when laterocervical lymph nodes (N1), distant metastasis (M1), or RET mutations, particularly M918T or indels, are already present at diagnosis, the role of IMTCGS in predicting DSS, DMFS, and LRFS becomes less relevant.
引用
- Prete A, Torregrossa L, Gambale C, et al. The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma. Thyroid. 2025. PMID: 39930944. doi:10.1089/thy.2024.0444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。